Skip to main content

ALVR

Stock
Health Care
Biotechnology

Performance overview

ALVR Price
Price Chart

Forward-looking statistics

Beta
1.09
Risk
84.44%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees121
Market cap$86.5M

Fundamentals

Enterprise value-$69.1M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$11.73
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$154K
Avg trading volume (10 day)$136K
Put-call ratio—

Macro factor sensitivity

Growth-1.8
Credit+7.2
Liquidity+1.5
Inflation-7.1
Commodities-1.5
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio-30.66
Price to sales—
P/E Ratio-30.66
Enterprise Value to Revenue—
Price to book0.43

Upcoming events

Next earnings dayMay 14, 2024
Next dividend day—
Ex. dividend day—

News

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Zacks Investment Research (January 29, 2024)
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Benzinga (January 16, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free